ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2024

A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer.

Pin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.